Opsens in first clinical use of OptoWire III after Health Canada approval

Opsens (TSX:OPS; OTCQX:OPSSF) announced the world’s first clinical use of its OptoWire III at the Quebec Heart and Lung Institute, following Health Canada’s recent approval of the device.

OptoWire III is a coronary guide wire integrating a second-generation optical sensor for vascular physiological measurement, such as fractional flow reserve. The pressure guide wire is designed to offer the lowest drift in the industry and excellent access to lesions. 

“While the high performance of the OptoWire II is recognized, our team made this product even better by responding to user improvement requests for complex lesions, particularly in the most tortuous and calcified arteries,” Opsens president and CEO, Louis Laflamme, said in a statement.

“Doctors will appreciate a design with increased maneuverability, strength and a shorter flexible tip,” he said. 

In addition to mechanical improvements, he said Opsens simplified and optimized the design of its flagship product, “giving the company more control and efficiency in its production line, which will result in improved profit margins.” 

In addition to Canada, Opsens has filed applications for approval in Japan, the U.S. and Europe.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.